CD44v6 和 RCAS1 在感染人乳头瘤病毒的宫颈癌中的表达及其对细胞增殖和分化的影响。
Expression of CD44v6 and RCAS1 in Uterine Cervical Carcinoma Infected with Human Papillomavirus and Its Effect on Cell Proliferation and Differentiation.
机构信息
Department of Pathology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
Pathology Diagnostic Center. 1011/2 Arun Ammarin Road, Siriraj, Bangkoknoi, Bangkok, Thailand.
出版信息
Asian Pac J Cancer Prev. 2022 Jul 1;23(7):2431-2439. doi: 10.31557/APJCP.2022.23.7.2431.
OBJECTIVE
To investigate the expression of CD44v6 and RCAS1 and the presence of HPV in cervical cancer tissues, to determine serum RCAS1 levels, and to evaluate these components in correlation with clinicopathologic features and survival.
METHODS
A total of 52 patients consisting of 28 squamous cell carcinoma (SCC) and 24 adenocarcinoma cases, were studied. RCAS1 and CD44v6 expression was evaluated using immunohistochemical staining. HPV 16 and 18 E6 genes were detected using PCR, and serum RCAS1 concentrations were measured using ELISA. Associations between these factors and clinicopathologic features and survival were analyzed.
RESULTS
CD44v6 expression was significantly higher in SCC compared with that in adenocarcinoma (P<0.001). It also showed a significant relation to histologic grade (P<0.001) and tumor size (P=0.03). RCAS1 expression was higher in adenocarcinoma than in SCC (P=0.001), and it showed a borderline relation with histological grade (P=0.057). Overall survival was not significantly different in both CD44v6 and RCAS1 expression; however, FIGO stage (P=0.025) and tumor size (P=0.042) resulted statistically different. The pre-surgical treatment serum RCAS1 levels were not associated with any clinicopathological variables. The presence of HPV 16 E6 was higher in SCC, while the presence of HPV 18 E6 was higher in adenocarcinoma (P<0.001). Detection of HPV 16 E6 was significantly associated with expression of CD44v6. The presence of HPV both HPV 16 E6 and HPV 18 E6 was found in cancer tissues with RCAS1 expression, but without any statistical significance.
CONCLUSION
CD44v6 and RCAS1 expression seems to be involved in tumor proliferation and differentiation, but it is not implicated in the progression and invasion of cervical cancer infected by HPV. Pre-treatment levels of serum RCAS1 in cervical cancer are not a diagnostic and predictive biomarker.
目的
研究 CD44v6 和 RCAS1 的表达以及 HPV 在宫颈癌组织中的存在情况，检测血清 RCAS1 水平，并评估这些成分与临床病理特征和生存的相关性。
方法
本研究共纳入 52 例患者，包括 28 例鳞癌（SCC）和 24 例腺癌病例。采用免疫组织化学染色法检测 RCAS1 和 CD44v6 的表达。采用 PCR 检测 HPV16 和 18 E6 基因，采用 ELISA 法检测血清 RCAS1 浓度。分析这些因素与临床病理特征和生存的关系。
结果
SCC 中 CD44v6 的表达明显高于腺癌（P<0.001），且与组织学分级（P<0.001）和肿瘤大小（P=0.03）显著相关。RCAS1 在腺癌中的表达高于 SCC（P=0.001），且与组织学分级呈临界相关（P=0.057）。CD44v6 和 RCAS1 的表达与总生存率无显著差异，但 FIGO 分期（P=0.025）和肿瘤大小（P=0.042）有统计学差异。术前治疗血清 RCAS1 水平与任何临床病理变量均无相关性。SCC 中 HPV16 E6 的检出率较高，而腺癌中 HPV18 E6 的检出率较高（P<0.001）。HPV16 E6 的检出与 CD44v6 的表达显著相关。RCAS1 表达阳性的癌组织中均检测到 HPV16 E6 和 HPV18 E6，但无统计学意义。
结论
CD44v6 和 RCAS1 的表达似乎参与了肿瘤的增殖和分化，但与 HPV 感染的宫颈癌的进展和侵袭无关。宫颈癌患者术前血清 RCAS1 水平不是诊断和预测的生物标志物。
Zotero 插件